Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 17/20 | 0.69 |
| ▸ | AURKB | Q96GD4 | 11/20 | 0.69 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.55 |
| ▸ | CSF1R | P07333 | 1/20 | 0.55 |
| ▸ | RET | P07949 | 1/20 | 0.55 |
| ▸ | FLT4 | P35916 | 1/20 | 0.55 |
| ▸ | ABL2 | P42684 | 1/20 | 0.55 |
| ▸ | BLK | P51451 | 1/20 | 0.55 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.55 |
| ▸ | SNCA | P37840 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL678881 | 0.88 | AURKA (0.71) | AURKAAURKBCHEK2CSF1RRET | |
| SCHEMBL679167 | 0.88 | AURKA (0.71) | AURKAAURKBCHEK2CSF1RRET | |
| SCHEMBL678582 | 0.87 | AURKA (0.70) | AURKAAURKBCHEK2CSF1RRET | |
| SCHEMBL678875 | 0.85 | AURKA (0.67) | AURKAAURKBCHEK2RETFLT4 | |
| SCHEMBL677909 | 0.84 | AURKA (0.67) | AURKAAURKBCHEK2CSF1RRET | |
| SCHEMBL679223 | 0.83 | AURKA (0.70) | AURKAAURKBCHEK2CSF1RRET | |
| SCHEMBL678945 | 0.82 | AURKA (0.68) | AURKAAURKBCHEK2RETFLT4 | |
| SCHEMBL679458 | 0.82 | AURKA (0.69) | AURKAAURKBCHEK2RETFLT4 | |
| SCHEMBL6524200 | 0.82 | AURKA (1.00) | AURKAAURKBCHEK2CSF1RRET | |
| SCHEMBL678106 | 0.81 | JAK2 (0.52) | AURKAAURKBCHEK2CSF1RRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269758-A1 | NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-11-03 | — | — | US | claimed |
| JP-2011526912-A | — | — | 2011-10-20 | — | — | JP | claimed |
| EP-2291376-A2 | NAPHTHYRIDININONES AS AURORA KINASE INHIBITORS | Merck Patent GmbH (DE) | 2011-03-09 | — | — | EP | claimed |
| WO-2010002779-A2 | NAPHTHYRIDININONES AS AURORA KINASE INHIBITORS | MERCK SERONO S.A. (CH) | 2010-01-07 | — | — | WO | claimed |
| US-20110269758-A1 | NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| US-20110269758-A1 | NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| EP-2291376-A2 | NAPHTHYRIDININONES AS AURORA KINASE INHIBITORS | Merck Patent GmbH (DE) | 2011-03-09 | — | — | EP | disclosed |
| WO-2010002779-A2 | NAPHTHYRIDININONES AS AURORA KINASE INHIBITORS | MERCK SERONO S.A. (CH) | 2010-01-07 | — | — | WO | disclosed |
| WO-2010002779-A2 | NAPHTHYRIDININONES AS AURORA KINASE INHIBITORS | MERCK SERONO S.A. (CH) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269758-A1 | NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS | AURKA, AURKC, AURKB | AURKA 1/4885AURKB 3/4885CHEK2 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.